TRIUMPH Study: Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations - Mark Markowski

October 24, 2018

(Length of Discussion: 12 min)

Alicia Morgans discusses with Mark Markowski details of the TRIUMPH trial, a single-arm, phase II trial, open-label using a PARP inhibitor rucaparib, in the absence of androgen deprivation therapy in men with metastatic hormone-naive prostate cancer.


Mark Christopher Markowski, MD., Ph.D., is a medical oncologist at the Kimmel Cancer Center at Sibley Memorial Hospital, as well as an instructor in the Department of Oncology at Johns Hopkins University School of Medicine. Dr. Markowski participates in multidisciplinary clinics at Sibley and The Johns Hopkins Hospital, and see patients in the genitourinary clinics of both hospitals. He is board certified in medical oncology and internal medicine by the American Board of Internal Medicine.  Dr. Markowski treats numerous types of cancers, with a specialty in prostate cancer.
Dr. Markowski earned his medical degree and Ph.D. in tumor biology at Georgetown University School of Medicine. He completed a residency in internal medicine at Columbia University, followed by a medical oncology fellowship at Johns Hopkins Hospital.

Alicia Morgans, MD, MPH

Read the Full Video Transcript